亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > Ganirelix加尼瑞克
Ganirelix加尼瑞克
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 1000g起訂1g
品牌 成都云希
CAS號 123246-29-7
外觀 白色粉末
過期 長期有效
更新 2021-07-21 15:06
 
詳細信息

Ganirelix

1.Basic information:

Name: Ganirelix

Synonym: Antagon;orgalutran;Ganirelixum

Cas No: 123246-29-7

Sequence: Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2

MF: C80H113ClN18O13

Molecular:1570.4

Purity:95%

Source: synthetic

Appearance: white powder


產品參數:


INCI名稱:加尼瑞克

形狀:白色粉末

PH:無

純度:95%

儲存條件:2~8℃密封避光儲存,長期存儲建議零下15~20℃冷藏最佳

安全性:無重金屬,無皮膚及眼刺激

包裝規格:1/

注意:本品為科研原料,不建議用于人體

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:41702  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |